1. Home
  2. EFSI vs CABA Comparison

EFSI vs CABA Comparison

Compare EFSI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

HOLD

Current Price

$40.05

Market Cap

214.3M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.45

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFSI
CABA
Founded
1881
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.3M
227.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EFSI
CABA
Price
$40.05
$2.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$39.50
$13.50
AVG Volume (30 Days)
15.1K
2.2M
Earning Date
10-23-2025
11-10-2025
Dividend Yield
3.09%
N/A
EPS Growth
N/A
N/A
EPS
2.13
N/A
Revenue
$66,122,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$27.28
N/A
P/E Ratio
$18.83
N/A
Revenue Growth
3.18
N/A
52 Week Low
$28.70
$0.99
52 Week High
$40.71
$3.67

Technical Indicators

Market Signals
Indicator
EFSI
CABA
Relative Strength Index (RSI) 77.71 50.80
Support Level $39.51 $2.32
Resistance Level $40.71 $2.48
Average True Range (ATR) 0.78 0.14
MACD 0.25 0.00
Stochastic Oscillator 98.36 31.58

Price Performance

Historical Comparison
EFSI
CABA

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: